Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and s...
May 4, 2026, 4:01 PM EDT - 12 days ago
2026-05-01T16:35:27.000Z - 15 days ago
Apr 30, 2026, 6:55 PM EDT - 15 days ago
Apr 10, 2026, 4:41 PM EDT - 5 weeks ago